Background
Helsinn Healthcare held patents on a specific 0.25 mg dose formulation of palonosetron (brand name Aloxi), a drug used to treat chemotherapy-induced nausea. In April 2001 — more than a year before the critical patent filing date — Helsinn entered into a license agreement and a supply and purchase agreement with MGI Pharma for the U.S. distribution of palonosetron. The agreements were publicly disclosed in MGI’s SEC filings (an 8-K report), but the specific dosage amounts and pricing terms were kept confidential and not revealed in the public filing. The public filing disclosed that an agreement for the supply of palonosetron had been executed, but not the specific 0.25 mg dose that was ultimately the subject of Helsinn’s patents.
When Teva sought to market a generic version of Aloxi under the Hatch-Waxman Act, Helsinn sued for infringement. Teva argued that Helsinn’s patents were invalid under the on-sale bar because of the 2001 agreement with MGI. The district court agreed with Helsinn, holding that the AIA’s amended § 102(b)(1)(A) — which requires that a sale be “otherwise available to the public” — altered the on-sale bar to require full public disclosure of the invention’s details, not merely public disclosure of the sale’s existence. Under that reading, Helsinn’s secret dosage details would not trigger the bar.
The Court’s Holding
The Federal Circuit reversed. The court held that the AIA did not fundamentally change the on-sale bar as applied to sales whose existence is publicly disclosed. After the AIA, if the existence of a sale agreement is public — as it was here, through the SEC filing — the details of the invention need not be publicly disclosed in the terms of the sale to trigger the bar. The court reasoned that the AIA’s amended § 102(b)(1)(A) language (“or otherwise available to the public”) added a new category of prior art for fully secret prior art disclosures, but did not eliminate the established rule that public commercial sales (even with confidential invention details) can invalidate a patent.
The sale to MGI had all the hallmarks of a binding commercial contract — price terms, delivery obligations, and mutual commitments — making it a “commercial offer for sale” or “sale” under the statute. The public disclosure of the agreement’s existence through SEC filings put the public on notice that a commercial arrangement had been made for the palonosetron product, satisfying the public dimension of the bar. The Supreme Court affirmed this ruling in January 2019.
Key Takeaways
- Under the AIA on-sale bar, if the existence of a commercial sale agreement is publicly disclosed (e.g., in an SEC filing or press release) more than one year before the patent application’s critical date, the sale can invalidate the patent even if the specific details of the claimed invention are kept confidential in the agreement.
- The AIA did not fundamentally change the on-sale bar for publicly disclosed sales — it primarily affected fully secret sales and activities that were not previously available to the public.
- Commercial supply agreements, licensing agreements, and distribution arrangements executed before the critical date can trigger the on-sale bar, particularly when publicly disclosed through SEC filings, press releases, or other public documents.
- The Supreme Court affirmed the Federal Circuit in Helsinn Healthcare v. Teva (2019), confirming that the pre-AIA rule about public commercial sales survives the AIA’s changes.
Why It Matters
Helsinn v. Teva is one of the most important pharmaceutical patent decisions of the decade for life sciences companies that execute commercial arrangements — including licensing deals, supply agreements, and distribution contracts — during the drug development and regulatory approval process. It is common practice for pharmaceutical companies to enter into commercial agreements with distributors or licensees while clinical trials are still ongoing and before the final patent applications are filed. Helsinn clarified that these pre-filing commercial arrangements can invalidate patents if they are publicly disclosed, even when invention details are kept confidential.
For drug companies, the ruling reinforces the importance of carefully timing patent filings relative to any commercial disclosure. If a supply agreement or licensing deal will be publicly disclosed (as required for SEC-reporting companies), the clock starts on the one-year grace period from the date of that disclosure, not from when the invention details become public. Companies must be prepared to file patent applications covering all commercially exploited inventions before their supply or licensing arrangements are disclosed to the public — or accept the risk that the bar will apply. Post-Helsinn, patent counsel advising on commercial transactions must closely review disclosure timelines against patent filing schedules to avoid inadvertent on-sale bar traps.